BPC-157 vs Retinalamin

BPC-157 and Retinalamin are both research peptides studied across multiple applications. This comparison examines their mechanisms, evidence base, and safety profiles to help researchers understand the key differences and overlaps.

BPC-157, a 15-amino-acid synthetic peptide (sequence: Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, MW ~1419.5 g/mol), is derived from a protein in human gastric juice. Preclinical studies have consistently demonstrated its regenerative and cytoprotective properties across various tissues, including tendons, ligaments, muscles, and the gastrointestinal tract. Notably, BPC-157 has shown promise in promoting healing in animal models of injury and inflammation. However, the clinical evidence in humans remains sparse, with only three pilot studies published by 2025, examining its effects in conditions such as knee pain (n=16), interstitial cystitis (n=12), and intravenous safety (n=2). The FDA categorizes BPC-157 as Category 2, restricting its compounding, and it is prohibited by the World Anti-Doping Agency (WADA) in sports contexts. While claims of enhanced healing and gut repair are prevalent, they are predominantly supported by preclinical findings, underscoring the need for further human studies.

Retinalamin is a polypeptide bioregulator derived from bovine retinal tissue, developed by Geropharm in Russia, with a focus on neuroprotection and retinal repair. Research indicates that it promotes the proliferation of retinal and pigmented epithelial cells, modulates neurotrophic factors such as brain-derived neurotrophic factor (BDNF), and offers protection against apoptosis in retinal cells. Clinical studies have reported significant improvements in visual acuity, with an 82% enhancement observed in pediatric cases of retinal abiotrophy and notable increases in retinal sensitivity among glaucoma patients. As a registered pharmaceutical in Russia, Retinalamin is utilized for conditions like glaucoma, diabetic retinopathy, and other retinal degenerative diseases. The evidence supporting its efficacy is derived from both preclinical and clinical studies, highlighting its potential role in enhancing visual outcomes and neuroprotection in ocular health.

BPC-157 and Retinalamin are primarily investigated within distinct research domains, with minimal overlap in their applications. BPC-157 is predominantly studied for its role in injury recovery, with a focus on the healing of tendons, ligaments, muscles, and bones, as well as its effects on gastrointestinal health, particularly in repairing the intestinal barrier and mitigating NSAID-induced damage. Conversely, Retinalamin is specifically targeted at eye health, emphasizing neuroprotection and the treatment of retinal degeneration, particularly in conditions such as glaucoma and diabetic retinopathy. While both peptides contribute to tissue repair, BPC-157 addresses systemic and musculoskeletal regeneration, whereas Retinalamin is specialized for ocular tissue health, underscoring their unique research niches.

The safety profile of BPC-157 is not well-characterized due to the absence of completed randomized controlled trials in humans. Preclinical studies across various animal models have not identified toxic or lethal doses within a range of 6 mcg/kg to 20 mg/kg, with no observed teratogenic, genotoxic, or anaphylactic effects noted in histopathological assessments. The FDA previously classified BPC-157 as Category 2 due to significant safety concerns, but it was removed from this category on April 15, 2026, pending a review by the Pharmacy Compounding Advisory Committee (PCAC) in July 2026 to evaluate compounding eligibility. In contrast, Retinalamin has demonstrated a favorable safety profile in clinical studies spanning up to two years, with minimal systemic adverse effects reported. However, local discomfort at the injection site may occur following parabulbar administration, which should be considered in its clinical use.